Advertisement: Mobas mid banner
Advertisement: KISS
ARM Innovation Hub
TTP
RealVNC mid-banner general
Advertisement: mid banner EY
Advertisement: Wild Knight Vodka
Advertisement: Cambridge Network
Advertisement: CPL mid banner
Barr Ellison Solicitors – commercial property
RealVNC mid banner careers
Advertisement: Cambridge Wireless
29 June, 2018 - 11:07 By Tony Quested

Cambridge alliance to fast-track drug discovery

phoremost, therapeutics, chris, torrance

Cambridge neighbours PhoreMost and o2h discovery have joined forces to accelerate the progress of drug discovery programmes.

PhoreMost is a biopharma company dedicated to drugging ‘undruggable’ disease targets. o2h discovery (o2h) is an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.

PhoreMost has built a pipeline of novel targets and early drug discovery programmes using its next-generation SITESEEKER® phenotypic screening platform. 

The collaboration will see o2h deploy its expertise in medicinal chemistry to help progress PhoreMost’s portfolio rapidly through the hit-to-lead and lead-optimisation stages of drug discovery.

PhoreMost CEO, Dr Chris Torrance (pictured above) said: “Since its inception, PhoreMost’s model has been to forge a new approach to drug discovery, working collaboratively with partners in order to progress new medicines. 

“The alliance with o2h truly reflects this and represents an important step in our mission to bring a greater diversity of therapies to patients, more quickly and at affordable prices.”

Sunil Shah, CEO of o2h discovery, added: “We have been impressed by the ability of PhoreMost’s SITESEEKER platform to systematically identify first-in-class drug targets in areas of high unmet need, and are excited to be applying our highly complementary capabilities to develop these potentially high value programs.

“Our shared vision of working collaboratively is also a testament to the strength of the Cambridge UK biotech cluster for discovery and progressing the next generation of therapeutics.”

PhoreMost recently announced the completion of an £11m ($15m) Series-A investment round. The investment will be used to expand operations on the Babraham Research Campus and progress several novel drug targets from the SITESEEKER platform into first-in-class drug discovery programmes. 

Newsletter Subscription

Stay informed of the latest news and features